Author

Frédérique Jantet-Blaudez

Observed name: Frederique Jantet-Blaudez

Institution: Sanofi (France)

Observed institution: Sanofi (France)

ORCID: 0000-0002-7139-9042

Observed ORCID: 0000-0002-7139-9042

OpenAlex ID: A5024399210

Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials

2016 · Anke Harenberg, Aymeric de Montfort, et al. · PLoS neglected tropical diseases · 18

Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4–5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial

2020 · Diana Coronel, Enid J. García-Rivera, et al. · The Pediatric Infectious Disease Journal · 8

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

2021 · Juliana Park, Sophia Archuleta, et al. · Human Vaccines & Immunotherapeutics · 7

Safety and immunogenicity of a cytomegalovirus (CMV) recombinant glycoprotein B (gB) vaccine in combination with polyacrylate or an emulsion-based adjuvants

2026 · Sylvie Pichon, Isabelle Bruyère, et al. · Vaccine · 1

Evaluation of the viability and functionality of human peripheral blood mononuclear cells cryopreserved up to 2 years in animal-protein-free freezing media compared to the FBS-supplemented reference medium

2025 · Frédérique Jantet-Blaudez, Joseline Ruiz, et al. · Frontiers in Immunology · 1

Works count: 5

Citation count: 35

H-index: 3

I10-index: 1